Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Validation of Limited Sampling Strategy for the Estimation of Mycophenolic Acid Exposure in Chinese Adult Liver Transplant Recipients

View through CrossRef
Mycophenolate mofetil (MMF) is indicated as immunosuppressive therapy in liver transplantation. The abbreviated models for the estimation of mycophenolic acid (MPA) area under the concentration-time curve (AUC) have been established by limited sampling strategies (LSSs) in adult liver transplant recipients. In the current study, the performance of the abbreviated models to predict MPA exposure was validated in an independent group of patients. A total of 30 MPA pharmacokinetic profiles from 30 liver transplant recipients receiving MMF in combination with tacrolimus were used to compare 8 models' performance with a full 10 time-point MPA-AUC. Linear regression analysis and Bland-Altman analysis were used to compare the estimated MPA-AUC0–12h from each model against the measured MPA-AUC0–12h. A wide range of agreement was shown when estimated MPA-AUC0–12h was compared with measured MPA-AUC0–12h, and the range of coefficient of determination (r 2) was from 0.479 to 0.936. The model based on MPA pharmacokinetic parameters C1h, C2h, C6h, and C8h had the best ability to predict measured MPA-AUC0–12h, with the best coefficient of determination (r 2 = 0.936), the excellent prediction bias (2.18%), the best prediction precision (5.11%), and the best prediction variation (2SD = ±7.88 mg · h/L). However, the model based on MPA pharmacokinetic sampling time points C1h, C2h, and C4h was more suitable when concerned with clinical convenience, which had shorter sampling interval, an excellent coefficient of determination (r 2 = 0.795), an excellent prediction bias (3.48%), an acceptable prediction precision (14.37%), and a good prediction variation (2SD = ±13.23 mg · h/L). Measured MPA-AUC0–12h could be best predicted by using MPA pharmacokinetic parameters C1h, C2h, C6h, and C8h. The model based on MPA pharmacokinetic parameters C1h, C2h, and C4h was more feasible in clinical application. Liver Transpl 13:1684–1693, 2007. © 2007 AASLD.
Title: Validation of Limited Sampling Strategy for the Estimation of Mycophenolic Acid Exposure in Chinese Adult Liver Transplant Recipients
Description:
Mycophenolate mofetil (MMF) is indicated as immunosuppressive therapy in liver transplantation.
The abbreviated models for the estimation of mycophenolic acid (MPA) area under the concentration-time curve (AUC) have been established by limited sampling strategies (LSSs) in adult liver transplant recipients.
In the current study, the performance of the abbreviated models to predict MPA exposure was validated in an independent group of patients.
A total of 30 MPA pharmacokinetic profiles from 30 liver transplant recipients receiving MMF in combination with tacrolimus were used to compare 8 models' performance with a full 10 time-point MPA-AUC.
Linear regression analysis and Bland-Altman analysis were used to compare the estimated MPA-AUC0–12h from each model against the measured MPA-AUC0–12h.
A wide range of agreement was shown when estimated MPA-AUC0–12h was compared with measured MPA-AUC0–12h, and the range of coefficient of determination (r 2) was from 0.
479 to 0.
936.
The model based on MPA pharmacokinetic parameters C1h, C2h, C6h, and C8h had the best ability to predict measured MPA-AUC0–12h, with the best coefficient of determination (r 2 = 0.
936), the excellent prediction bias (2.
18%), the best prediction precision (5.
11%), and the best prediction variation (2SD = ±7.
88 mg · h/L).
However, the model based on MPA pharmacokinetic sampling time points C1h, C2h, and C4h was more suitable when concerned with clinical convenience, which had shorter sampling interval, an excellent coefficient of determination (r 2 = 0.
795), an excellent prediction bias (3.
48%), an acceptable prediction precision (14.
37%), and a good prediction variation (2SD = ±13.
23 mg · h/L).
Measured MPA-AUC0–12h could be best predicted by using MPA pharmacokinetic parameters C1h, C2h, C6h, and C8h.
The model based on MPA pharmacokinetic parameters C1h, C2h, and C4h was more feasible in clinical application.
Liver Transpl 13:1684–1693, 2007.
© 2007 AASLD.

Related Results

Hepatitis E Viraemia in Transplant Recipients
Hepatitis E Viraemia in Transplant Recipients
Abstract Introduction: Hepatitis E Virus (HEV) is one of the leading causes of acute infectious hepatitis worldwide; while usually a s...
An internet-based expressive writing intervention for kidney transplant recipients
An internet-based expressive writing intervention for kidney transplant recipients
Background: Previous research has found that psychiatric problems and stress in kidney transplant recipients negatively impact upon their quality of life (QOL) and how they heal fr...
Validation in Doctoral Education: Exploring PhD Students’ Perceptions of Belonging to Scaffold Doctoral Identity Work
Validation in Doctoral Education: Exploring PhD Students’ Perceptions of Belonging to Scaffold Doctoral Identity Work
Aim/Purpose: The aim of this article is to make a case of the role of validation in doctoral education. The purpose is to detail findings from three studies which explore PhD stude...
De Novo Colorectal and Pancreatic Cancer in Liver‐Transplant Recipients: Identifying the Higher‐Risk Populations
De Novo Colorectal and Pancreatic Cancer in Liver‐Transplant Recipients: Identifying the Higher‐Risk Populations
Background and Aims Gastrointestinal (GI) malignancies are common after liver transplantation. The aim of this study was to identify the risk and timing of the more com...
Percutaneous Coronary Intervention Outcomes in Solid Organ Transplant Candidates
Percutaneous Coronary Intervention Outcomes in Solid Organ Transplant Candidates
Background: As part of the pre-transplant assessment, patients with end-stage renal, liver, pancreas, or lung disease who wish to attain transplant eligibility must undergo evaluat...
Drug Usage and Risk for Polypharmacy After Pediatric Solid Organ Transplantation—A National Register Study
Drug Usage and Risk for Polypharmacy After Pediatric Solid Organ Transplantation—A National Register Study
ABSTRACTBackgroundSolid organ transplant (SOT) recipients are at risk for long‐term comorbidities and polypharmacy, potentially affecting quality of life. This study assessed the p...
Immunosuppressant nonadherence profile in kidney transplant recipients and the impact of medication adherence on transplant outcomes
Immunosuppressant nonadherence profile in kidney transplant recipients and the impact of medication adherence on transplant outcomes
BackgroundDespite the fact that 1-year graft and recipient survival rates are above 90% in most transplant centers, improving long-term graft survival remains an important challeng...

Back to Top